- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07576348
Electroacupuncture for Insomnia in Patients With Chronic Sciatica Due to Lumbar Disc Herniation: a Randomized Controlled Trial
4 de maio de 2026 atualizado por: Shanghai Yueyang Integrated Medicine Hospital
The goal of this clinical trial is to learn if electroacupuncture can improve sleep in people with chronic sciatica caused by lumbar disc herniation.
It will also assess the safety of this treatment.
The main questions it aims to answer are whether electroacupuncture improves sleep quality and whether it reduces pain and improves daily function.
Researchers will compare electroacupuncture to a sham treatment, which looks like real acupuncture but has little or no therapeutic effect, to determine its effectiveness.
Participants will be randomly assigned to receive electroacupuncture or sham treatment, will receive treatment three times per week for four weeks, and will complete questionnaires about their sleep, pain, and daily activities.
Visão geral do estudo
Status
Ainda não está recrutando
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
114
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Ke Wang
- Número de telefone: +86 21-65161782-3136
- E-mail: wangke8430@163.com
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
Participants will be eligible if they meet all of the following criteria:
- Aged 18-75 years, of either sex;
- Diagnosis with lumbar disc herniation accompanied by unilateral chronic sciatica (disease duration ≥ 3 months);
- Experiencing moderate to severe radiating leg pain (below the knee), defined as a Numerical Rating Scale (NRS) score ≥ 4 at screening within the past 24 h;
- Diagnosis of chronic insomnia, with a Pittsburgh Sleep Quality Index (PSQI) total score > 7;
- Onset or exacerbation of insomnia temporally associated with the onset or worsening of sciatica symptoms;
- Willing to participate and able to provide written informed consent.
Exclusion Criteria:
Participants will be excluded if any of the following criteria are met:
- Spinal or structural conditions: lumbar spinal stenosis, spondylolisthesis, vertebral fracture, spinal infection (e.g., tuberculosis), or tumor;
- Surgical indications: cauda equina syndrome, conus medullaris syndrome, or other conditions requiring urgent surgical intervention;
- Severe systemic diseases: unstable cardiovascular, hepatic, renal, respiratory, or hematological disorders, or metabolic conditions that may significantly affect study outcomes (e.g., uncontrolled diabetes or thyroid disease);
- Neurological or psychiatric disorders: major neurological diseases (e.g., epilepsy, Parkinson's disease, dementia, multiple sclerosis) or severe psychiatric disorders (e.g., schizophrenia);
- Clinically significant depression or anxiety, defined as Patient Health Questionnaire-9 (PHQ-9) ≥ 10 and/or Generalized Anxiety Disorder-7 (GAD-7) ≥ 10;
- Other primary sleep disorders, including obstructive sleep apnea, narcolepsy, or restless legs syndrome;
- Use of centrally acting medications: regular use (≥ 3 days/week within 4 weeks prior to enrolment) of medications affecting the central nervous system (e.g., opioids, sedative-hypnotics, antidepressants) without an adequate washout period (≥ 2 weeks or longer depending on drug half-life);
- Irregular sleep patterns, including night shift work (≥ 2 times/week between 22:00-06:00) or highly irregular sleep-wake cycles;
- Pregnancy or lactation;
- History of substance abuse or dependence;
- Lumbar spine surgery or interventional procedures within the past 3 months;
- History of acupuncture treatment;
- Implanted electronic devices (e.g., pacemakers) or metal implants at acupuncture sites;
- Participation in another clinical trial within the past 3 months;
- Severe sensory or cognitive impairment affecting assessment compliance;
- Any other condition deemed by investigators to compromise safety or data integrity.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Eletroacupuntura
|
Electroacupuncture will be administered by a licensed acupuncturist.
Adhesive foam pads will be applied at each acupoint to enhance blinding.
Sterile needles will be inserted through the pads into the skin at predefined acupoints, including Sishencong (EX-HN1), bilateral Shenmen (HT7) and Sanyinjiao (SP6), Jiaji (EX-B2) at the L3-L5 levels (bilateral points at each segment), Shenshu (BL23), Dachangshu (BL25), and selected lower limb acupoints.
Electrical stimulation will be applied using a sparse-dense wave (2/10 Hz) for 30 minutes per session.
Treatment will be delivered three times per week for four weeks.
|
|
Comparador Falso: Eletroacupuntura simulada
|
Sham electroacupuncture will be administered by a licensed acupuncturist.
Adhesive foam pads will be applied at each non-acupoint to maintain blinding.
Sterile needles will be inserted superficially (2-3 mm) through the pads without manipulation or eliciting deqi sensation.
Electrical stimulation will be minimally applied only briefly at the beginning and end of each session to mimic the procedure.
Treatment duration and frequency will be identical to the electroacupuncture group (30 minutes per session, three times per week for four weeks).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pittsburgh Sleep Quality Index (PSQI) total score
Prazo: Week 4
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.
|
Week 4
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Numerical Rating Scale (NRS) score for leg pain intensity
Prazo: Baseline, Week 2, Week 4, and Week 8
|
The 11-point Numerical Rating Scale (NRS) is a self-reported instrument used to assess average radiating leg pain intensity over the preceding 24 hours, with scores ranging from 0 to 10, where higher scores denote more severe pain.
|
Baseline, Week 2, Week 4, and Week 8
|
|
Numerical Rating Scale (NRS) score for low back pain intensity
Prazo: Baseline, Week 4, and Week 8
|
The 11-point Numerical Rating Scale (NRS) is a self-reported instrument used to assess average low back pain intensity over the preceding 24 hours, with scores ranging from 0 to 10, where higher scores denote more severe pain.
|
Baseline, Week 4, and Week 8
|
|
Oswestry Disability Index (ODI) score
Prazo: Baseline, Week 4, and Week 8
|
The Oswestry Disability Index (ODI) is a self-reported questionnaire used to assess disability related to lumbar spine disorders, with percentage scores ranging from 0% to 100%, where higher scores denote greater disability.
|
Baseline, Week 4, and Week 8
|
|
Insomnia Severity Index (ISI) score
Prazo: Baseline, Week 2, Week 4, and Week 8
|
The Insomnia Severity Index (ISI) is a self-reported instrument used to assess the subjective severity of insomnia, its impact on daytime functioning, and associated distress over the preceding two weeks, with total scores ranging from 0 to 28, where higher scores denote more severe insomnia.
|
Baseline, Week 2, Week 4, and Week 8
|
|
Pittsburgh Sleep Quality Index (PSQI) total score
Prazo: Week 8
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.
|
Week 8
|
|
Proportion of participants achieving ≥50% reduction in Pittsburgh Sleep Quality Index (PSQI) total score
Prazo: Week 4, Week 8
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.
|
Week 4, Week 8
|
|
Sleep efficiency measured by actigraphy
Prazo: Baseline, Week 4
|
Baseline, Week 4
|
|
|
Total sleep time measured by actigraphy
Prazo: Baseline, Week 4
|
Baseline, Week 4
|
|
|
Incidence of adverse events
Prazo: From baseline to Week 8
|
From baseline to Week 8
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Resting-state electroencephalography-derived microstate parameters
Prazo: Baseline, Week 4
|
Resting-state electroencephalography-derived microstate parameters, including mean duration, occurrence rate, time coverage, and transition probability, will be assessed at baseline and week 4. Mean duration refers to the average time for which a microstate class remains stable; occurrence rate refers to the number of occurrences per second; time coverage refers to the percentage of total recording time occupied by a microstate class; and transition probability refers to the probability of transition from one microstate class to another.
|
Baseline, Week 4
|
|
Untargeted plasma metabolomic features
Prazo: Baseline, Week 4
|
Fasting plasma samples will be collected at baseline and week 4 and analyzed using an untargeted metabolomics approach based on ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS).
Detected metabolomic features will be characterized by mass-to-charge ratio, retention time, relative ion intensity, and tandem mass spectrometry spectra.
|
Baseline, Week 4
|
|
Credibility/Expectancy Questionnaire scores
Prazo: Baseline
|
Treatment credibility and expectancy will be assessed before treatment using the Credibility/Expectancy Questionnaire.
The credibility subscale consists of three items rated on a 1-9 scale, with a total score ranging from 3 to 27; higher scores indicate greater perceived treatment credibility.
The expectancy subscale consists of three items assessing expected improvement and perceived treatment benefit.
Two items are rated from 0% to 100%, and one item rated on a 1-9 scale will be transformed to a 0-100 scale; the three items will be averaged to generate a score ranging from 0 to 100, with higher scores indicating greater treatment expectancy.
|
Baseline
|
|
Bang blinding index
Prazo: Week 4
|
At week 4, before unblinding, participants will complete a structured blinding assessment question asking them to guess their treatment allocation as real electroacupuncture, sham electroacupuncture, or "uncertain."
Blinding success will be quantified using the Bang blinding index and its 95% confidence interval.
The Bang blinding index ranges from -1 to 1, with values close to 0 indicating successful blinding.
Values between -0.2 and 0.2 will be interpreted as indicating adequate blinding.
|
Week 4
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de maio de 2026
Conclusão Primária (Estimado)
1 de fevereiro de 2027
Conclusão do estudo (Estimado)
1 de março de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
28 de abril de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
4 de maio de 2026
Primeira postagem (Real)
8 de maio de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
8 de maio de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
4 de maio de 2026
Última verificação
1 de maio de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Dor
- Manifestações Neurológicas
- Doenças ósseas
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Condições Patológicas, Anatômicas
- Doenças Neuromusculares
- Doenças do Sistema Nervoso Periférico
- Doenças da coluna vertebral
- Distúrbios do Sono Vigília
- Hérnia
- Distúrbios do Sono Intrínsecos
- Dissônias
- Neuralgia
- Mononeuropatias
- Neuropatia ciática
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Deslocamento do Disco Intervertebral
- Distúrbios de Iniciação e Manutenção do Sono
- Ciática
- Terapêutica
- Terapias complementares
- Modalidades de fisioterapia
- Reabilitação
- Anestesia e analgesia
- Terapia de estimulação elétrica
- Terapia de modalidade combinada
- Anestesia
- Analgesia
- Terapia de acupuntura
- Estimulação do nervo elétrico transcutâneo
- Eletroacupuntura
Outros números de identificação do estudo
- 2026-084
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .